Clinical Trials Browser

Phase 2 × Active not recruiting × trastuzumab deruxtecan × Clear all

NCT04482309 2026-04-09

DPT02

Phase 2 Active not recruiting

477 enrolled 2 FDA

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT05034887 2026-04-08

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Gastric Adenocarcinoma

NCT05480384 2026-04-01

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Phase 2 Active not recruiting

Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT04639219 2026-03-23

DPT01

Phase 2 Active not recruiting

102 enrolled 18 charts

Neoplasm Metastasis

NCT06048718 2026-03-10

TUXEDO-4

Phase 2 Active not recruiting

Brain Neoplasms, Breast Neoplasms

NCT05704829 2025-11-19

ADAPTHER2-IV

Phase 2 Active not recruiting

Recurrence

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT05246514 2025-08-28

DL-05

Phase 2 Active not recruiting

72 enrolled 16 charts

HER2-mutant Non-Small Cell Lung Cancer

NCT05710666 2024-08-05

Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)

Phase 2 Active not recruiting

HER2-positive Breast Cancer